Thomas R. Staab II, Senior Vice President and CFO at BIOCRYST PHARMACEUTICALS INC (BCRX), sold 6,500 shares at $8.20 ($55K) on 2017-03-08, disclosed to the SEC on 2017-03-10.
Scheduled sale ($55k) by Senior Vice President and CFO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $8.20 | 3,250 | $27K | 48.7% |
| 2 | $8.65 | 3,250 | $28K | 51.3% |
| Total | $8.43 avg | 6,500 | $55K | 100% |
| Filing → |
| BCRX | SELL | 2019-05-16 | $92K | — | Filing → |
| BCRX | SELL | 2019-05-13 | $224K | — | Filing → |
| BCRX | SELL | 2019-05-06 | $126K | — | Filing → |